Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ju, yunfei
NCT05758519: A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19	Not yet recruiting	3	1220	RoW	QLS1128, Placebo	Qilu Pharmaceutical Co., Ltd.	COVID-19	06/23	06/23
NCT06633718: Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI	Not yet recruiting	3	786	RoW	Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam, Metronidazole	Qilu Pharmaceutical Co., Ltd.	Intra-abdominal Infections	05/27	05/27
NCT05689203: A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19	Recruiting	2	360	RoW	QLS1128, Placebo	Qilu Pharmaceutical Co., Ltd.	COVID-19	02/23	02/23
NCT05458076: A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants	Recruiting	1	86	RoW	QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir	Qilu Pharmaceutical Co., Ltd.	COVID-19	09/22	09/22

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ju, yunfei
NCT05758519: A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19	Not yet recruiting	3	1220	RoW	QLS1128, Placebo	Qilu Pharmaceutical Co., Ltd.	COVID-19	06/23	06/23
NCT06633718: Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI	Not yet recruiting	3	786	RoW	Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam, Metronidazole	Qilu Pharmaceutical Co., Ltd.	Intra-abdominal Infections	05/27	05/27
NCT05689203: A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19	Recruiting	2	360	RoW	QLS1128, Placebo	Qilu Pharmaceutical Co., Ltd.	COVID-19	02/23	02/23
NCT05458076: A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants	Recruiting	1	86	RoW	QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir	Qilu Pharmaceutical Co., Ltd.	COVID-19	09/22	09/22